DDInter584 DDInter1376
One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dopamine {u} (Compound) resembles {v} (Compound) Dobutamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Dopamine {u} (Compound) resembles {v} (Compound) Epinephrine
Dopamine {u} (Compound) binds {v} (Gene) HTR7
Dopamine {u} (Compound) upregulates {v} (Gene) KIF14
Dopamine {u} (Compound) is included by {v} (Pharmacologic Class) Catecholamines
Dopamine {u} (Compound) downregulates {v} (Gene) CEP57
Dopamine {u} (Compound) causes {v} (Side Effect) Gangrene
Dopamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metoclopramide
Dopamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Dopamine (Compound) resembles Dobutamine (Compound)
Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Dopamine (Compound) resembles Epinephrine (Compound)
Dopamine (Compound) binds HTR7 (Gene)
Dopamine (Compound) upregulates KIF14 (Gene)
Dopamine (Compound) is included by Catecholamines (Pharmacologic Class)
Dopamine (Compound) downregulates CEP57 (Gene)
Dopamine (Compound) causes Gangrene (Side Effect)
Dopamine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Dopamine may cause a minor interaction that can limit clinical effects when taken with Lidocaine